{
      "official_url": "https://sirpublishers.org/index.php/JAMS/article/view/178",
      "subjects": [
        "gut microbiome",
        "oncology",
        "immunotherapy"
      ],
      "userid": 1,
      "note": "Imported from SIR Publishers (OAI id oai:ojs2.sirpublishers.org:article/178)",
      "date_type": "published",
      "metadata_visibility": "show",
      "ispublished": "pub",
      "uri": "https://arxiv.universalpublishings.com/id/eprint/51369",
      "date": "2026-05-30",
      "id_number": "oai:ojs2.sirpublishers.org:article/178",
      "full_text_status": "none",
      "type": "article",
      "eprint_status": "archive",
      "lastmod": "2026-05-26 15:31:04",
      "publication": "JOURNAL OF APPLIED MEDICAL SCIENCES",
      "dir": "disk0/00/05/13/69",
      "sword_depositor": 1,
      "keywords": "gut microbiome; oncology; immunotherapy",
      "eprintid": 51369,
      "creators": [
        {
          "name": {
            "honourific": null,
            "given": "NAJMIDDIN",
            "family": "XABIBULLAYEV",
            "lineage": null
          }
        },
        {
          "name": {
            "honourific": null,
            "given": "HAKIM",
            "lineage": null,
            "family": "TO\u2018YCHIYEV"
          }
        }
      ],
      "abstract": "In recent years, the gut microbiome has been increasingly recognized as a key modifiable\ndeterminant of both the efficacy and safety of anticancer therapy. Growing clinical and experimental\nevidence indicates that microbial community structure and, more importantly, functional capacity can\nshape systemic immune tone, inflammatory signaling, and host\u2013microbe metabolic outputs (including\nshort-chain fatty acids, tryptophan-derived metabolites, and bile acid transformation). Through these\npathways, the microbiome may influence tumor immune microenvironment features and the\nlikelihood of response or resistance to modern treatments, particularly immune checkpoint inhibitors\ntargeting PD-1/PD-L1 and CTLA-4. In parallel, the microbiome can contribute to treatment-related \ntoxicity by modulating drug metabolism and mucosal immunity, thereby affecting the risk and\nseverity of immune-related adverse events (irAEs) and gastrointestinal complications. This article\nsynthesizes current mechanistic concepts and translational findings linking the microbiome to\noncologic outcomes and evaluates microbiotechnology-driven strategies for targeted microbiome\nmodulation, including fecal microbiota transplantation, live biotherapeutic products (defined\nmicrobial consortia), prebiotic and postbiotic interventions, metabolite-oriented approaches, and\nselective inhibition of specific bacterial enzymes as a rational route to reduce toxicity while\npreserving anticancer activity. Particular attention is paid to practical barriers to implementation\u2014\nstandardization, biosafety, reproducibility, regulatory requirements, and major confounders such as\nantibiotic exposure, diet, and concomitant medications\u2014which complicate causal inference and limit\nbroad clinical adoption. Overall, the evidence supports the promise of personalized, biomarker\ninformed microbiome modulation as an adjunct strategy to enhance therapeutic benefit and mitigate\nadverse effects, provided that efficacy and safety are confirmed in well-controlled clinical trials.",
      "status_changed": "2026-05-26 15:31:02",
      "title": "THE MICROBIOME FACTOR IN ONCOLOGY: ENHANCING DRUG EFFICACY AND  REDUCING ADVERSE EFFECTS THROUGH MICROBIOTECHNOLOGICAL  MODULATION",
      "datestamp": "2026-05-26 15:31:02",
      "rev_number": 1,
      "publisher": "SIR Publishers"
    }